[High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison].
We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated. The clinical course of AUGIH was evaluated, if emergency endoscopy revealed lesions substantially dependent on intragastric acidity with respect to pathogenesis and/or healing (peptic ulcer, erosive gastroduodenitis, reflux-esophagitis, Mallory-Weiss tears) and patients either received a combined therapy of famotidine (20 mg i.v. every 12 hrs), pirenzepine (10 mg i.v. every 12 hrs) and antacid (control group: n = 96) or omeprazole (40 mg i.v. every 6 hrs; omeprazole group: n = 100). Rate of rebleeding was lower in the omeprazole group without reaching significance (12 vs. 21; p = 0.06). No difference was found for rates of operation (6 vs. 6; p = 0.94), death from bleeding (5 vs. 9; p = 0.22), transfusions ([mean +/- SD] 3.3 +/- 5.0 vs. 3.2 +/- 5.7; p = 0.51) and hospitalisation ([mean +/- SD] 26.8 +/- 12.1 vs. 27.8 +/- 16.0 days; p = 0.88). Considering prognostic risk factors (age > or = 65, actively bleeding lesion, initial state of shock) logistic regression showed that high dose omeprazole inhibited rebleeding (p = 0.01) but had no effect as regards surgery or mortality. Within two selected subgroups defined by additional criteria (no endoscopic treatment and anamnestic peptic lesion) omeprazole-treated cases showed lower rates of rebleeding (3/49 vs. 12/54, p " 0.02 and 3/44 vs. 13/48, p = 0.01 resp.) and death from bleeding (0/46 vs. 6/50, p = 0.03 and 0/43 vs. 5/45, p = 0.03 resp.).(ABSTRACT TRUNCATED AT 250 WORDS)
Busam
J
J
Medizinische Abteilung B, Krankenhaus Rissen, Hamburg.
Garbe
W E
WE
D000368:Aged; D000369:Aged, 80 and over; D000536:Aluminum Hydroxide / Q000008:administration & dosage* / Q000009:adverse effects; D000863:Antacids / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D016145:Endoscopy, Digestive System; D015738:Famotidine / Q000008:administration & dosage* / Q000009:adverse effects; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D006801:Humans; D008276:Magnesium Hydroxide / Q000008:administration & dosage* / Q000009:adverse effects; D009853:Omeprazole / Q000008:administration & dosage* / Q000009:adverse effects; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D010890:Pirenzepine / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate
D000863:Antacids; D010890:Pirenzepine; D000536:Aluminum Hydroxide; D015738:Famotidine; C016545:magaldrate; D009853:Omeprazole; D008276:Magnesium Hydroxide
Omeprazol hochdosiert versus Famotidin, Pirenzepin und Antazidum in der Therapie der akuten oberen gastrointestinalen Blutung im retrospektiven Vergleich.